BCR/ABL: from molecular mechanisms of leukemia induction to treatment of chronic myelogenous leukemia.
Salesse
Stephanie
S
Stem Cell Institute, Cancer Center and Department of Medicine, University of Minnesota Cancer Center, Minneapolis, Minnesota, MN 55455, USA.
Verfaillie
Catherine M
CM
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D016044:Fusion Proteins, bcr-abl; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000235:genetics* / Q000503:physiopathology; D011505:Protein-Tyrosine Kinases / Q000235:genetics / Q000378:metabolism*; D015398:Signal Transduction / Q000187:drug effects
D000970:Antineoplastic Agents; D011505:Protein-Tyrosine Kinases; D016044:Fusion Proteins, bcr-abl